中等度から重症関節リウマチ患者における、トファシチニブ vs 生物学的製剤のネットワークメタ解析
J Clin Pharm Ther. 2019 Jun;44(3):384-396.
This study suggests that many bDMARDs and tsDMARDs can be considered equivalent therapeutic alternatives in bDMARD-naïve RA patients, with inadequate response to csDMARDs.In the absence of randomised controlled trials comparing drugs, indirect comparisons and network meta-analysis may provide information to help select an optimal treatment alternative. In this network meta-analysis, 27 randomized controlled trials were analysed to assess the possibility that some drugs on the market may be consi...